Explore the vast range of titles available.

A bstract We present the complete cross-section for the production of unpolarized hadrons in semi-inclusive deep-inelastic scattering up to power-suppressed O 1 / Q 2 terms in the Wandzura-Wilczek-type approximation, which consists in systematically assuming that q ¯ g q -terms are much smaller than q ¯ q -correlators. We compute all twist-2 and twist-3 structure functions and the corresponding asymmetries, and discuss the applicability of the Wandzura-Wilczek-type approximations on the basis of available data. We make predictions that can be tested by data from COMPASS, HERMES, Jefferson Lab, and the future Electron-Ion Collider. The results of this paper can be readily used for phenomenology and for event generators, and will help to improve the description of semi-inclusive deep-inelastic processes in terms of transverse momentum dependent parton distribution functions and fragmentation functions beyond the leading twist.

The concept of weighted asymmetries is revisited for semi-inclusive deep inelastic scattering. We consider the cross section in Fourier space, conjugate to the outgoing hadron’s transverse momentum, where convolutions of transverse momentum dependent parton distribution functions and fragmentation functions become simple products. Individual asymmetric terms in the cross section can be projected out by means of a generalized set of weights involving Bessel functions. Advantages of employing these Bessel weights are that they suppress (divergent) contributions from high transverse momentum and that soft factors cancel in (Bessel-)weighted asymmetries. Also, the resulting compact expressions immediately connect to previous work on evolution equations for transverse momentum dependent parton distribution and fragmentation functions and to quantities accessible in lattice QCD. Bessel-weighted asymmetries are thus model independent observables that augment the description and our understanding of correlations of spin and momentum in nucleon structure.

Background: Cladribine is a synthetic deoxyadenosine analogue in development as an oral multiple sclerosis (MS) therapy. Objective: To report in detail the safety findings from the 96-week, phase III, double-blind CLARITY study, which evaluated treatment with cladribine tablets in relapsing–remitting MS. Methods: A total of 1,326 patients were randomized 1 : 1 : 1 to two short-course regimens of cladribine tablets (3.5 or 5.25 mg/kg cumulative dose over 96 weeks) or placebo. Safety assessments included monitoring for adverse events (AEs), routine physical and neurologic examinations and frequent laboratory parameter assessments. Results: Of the randomized patients, 88.6% completed treatment with cladribine tablets versus 86.3% with placebo. Lymphopenia was the most commonly reported AE in patients treated with cladribine tablets and was anticipated based on the mechanism of action. The incidence of infections was 48.3% with cladribine tablets and 42.5% with placebo, with 99.1% and 99.0% rated mild-to-moderate by investigators. Herpes zoster infections developed in 20 (2.3%) cladribine-treated patients; all cases were dermatomal. There were no herpes zoster infections in the placebo group. Nine (1.0%) patients experienced events related to uterine leiomyomas in the cladribine tablets groups versus one (0.2%) with placebo. Three isolated cases of malignancy were reported in cladribine-treated patients during the study; a fourth was reported during post-study surveillance. A pre-malignant cervical carcinoma in situ was also reported. The incidence of malignancies during the study did not exceed the expected rate in a population standardized for country, gender and age. Conclusion: The safety and tolerability profile observed in the CLARITY study together with the reported efficacy support the potential for cladribine tablets as an MS therapy.

In addition to treating the motor symptoms of Parkinson's disease, the dopamine agonist pramipexole has shown an antidepressant effect. The trials, however, included patients with motor complications, raising the question of whether the antidepressant benefit represented only a treatment-related motor improvement. To address this issue, we have conducted a 14-week randomized trial comparing pramipexole with an established antidepressant in patients without motor complications. At seven Italian centers, 67 Parkinsonian outpatients with major depression but no history of motor fluctuations and/or dyskinesia received open-label pramipexole (at 1.5 to 4.5 mg/day) or sertraline (at 50 mg/day). In both groups, the Hamilton Depression Rating Scale (HAM-D) score decreased throughout 12 weeks of treatment, but in the pramipexole group the proportion of patients who recovered, as defined by a final HAM-D score